Aakaar
enhancing life through technology
CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

11th February, 2026

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C-1, Block G
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051.

NSE Symbol: AAKAAR

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Product Launch Information

Dear Sir/Madam,

Further to our letter dated 13.8.2025 and pursuant to Regulation 30 read with Para B of Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. SEBI/HO/CFD/PoD/CIR/P/2023/120 dated July 13, 2023, the details with respect to the following product launch are disclosed as under:

Sr. No.	Name of th Product	Date of Launch	Category of Product	Whether caters to domestic/ internation al market	Name of the countries in which the product is launched (in case of international)
Hugel Inc. Korea					
1	Letybo	2nd week of April, 2026	Drug (Botulinum toxin)	Domestic	-

A press release of the same is enclosed to this intimation and will also be made available on the Company's website at www.aakaarmedical.in

CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

You are requested to take the above information on your record.

Thanking you,

Yours truly,
For Aakaar Medical Technologies Limited,

VISHWANATHAN ANOOPKUMAR PILLAI

Digitally signed by VISHWANATHAN ANOOPKUMAR PILLAI
Date: 2026.02.11 18:11:15 +05'30'

Anoopkumar Pillai
Company Secretary & Compliance Officer

Encl.: As above

Aakaar
enhancing life through technology
CIN No.: L74900MH2013PLC244717

Aakaar Medical Technologies Limited
(formerly: Aakaar Medical Technologies Pvt.Ltd.)
A-801, Heritage Plaza, Teli Gali Cross Road
Andheri (East), Mumbai – 400 069 INDIA
Mob: + 91 9820317468
E-mail: info@aakaarmedical.in
www.aakaarmedical.in
GST No: 27AALCA7587Q1ZK

Press Release

Letybo® USFDA-Approved Botulinum Toxin – India Launch

Aakaar Medical Technologies Ltd has received the import license to market Letybo, a USFDA-approved botulinum toxin, under its strategic tie-up with Hugel. Commercial marketing is scheduled to commence from April, 2026.

Strategic and Market Impact

Entry into an established USFDA segment: Letybo joins the cohort of USFDA-approved toxins already present in India, including Botox, Nabota, Xeomin, and Dysport, reinforcing Aakaar's credibility within the highest regulatory standard category.

Enhanced doctor confidence: USFDA approval materially improves physician trust, safety perception, and protocol acceptance, supporting faster adoption in premium and institutional practices.

Deeper market penetration: Availability of a 50 IU vial enables flexible pricing, lower entry thresholds for new injectors, and broader reach across tier-2 and tier-3 markets.

High-growth category exposure: Botulinum toxin is the largest recurring-use segment in medical aesthetics, benefiting from repeat treatments and expanding cosmetic and therapeutic indications.

Portfolio leverage: Letybo strengthens Aakaar's injectable platform and complements its USFDA-aligned dermal fillers and devices, enabling bundled offerings and higher clinic wallet share.

This launch positions Aakaar competitively within India's USFDA-approved toxin landscape, combining regulatory credibility, pricing flexibility via 50 IU vials, and strong physician support to drive adoption and growth.

For Aakaar Medical Technologies Ltd.

Rahul Babasaheb Sawakhande

Digitally signed by Rahul Babasaheb Sawakhande
Date: 2026.02.11 18:09:54 +05'30'

Dr. Rahul B. Sawakhande
CEO & Director

Mumbai
11.02.2026